Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas - PubMed (original) (raw)
. 1995 May 4;10(9):1813-21.
Affiliations
- PMID: 7538656
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
M Alimandi et al. Oncogene. 1995.
Abstract
In the present study we demonstrate that erbB-3 and erbB-2 cooperate in neoplastic transformation. Under conditions in which neither gene alone induced transformation, they readily transformed NIH3T3 cells if co-expressed. Furthermore, at high expression levels of ErbB2 which cause transformation, ErbB3 enhanced focus formation by one order of magnitude. Synergy required an intact ErbB2 extracellular domain and tyrosine kinase activity. Cooperation between ErbB3 and ErbB2 involved heterodimerization and increased tyrosine phosphorylation of ErbB3. Signaling by the heterodimer resulted in increased PI 3-kinase recruitment as well as quantitative and qualitative differences in substrate phosphorylation. Evidence for signaling by an active ErbB3-ErbB2 heterodimer in four mammary tumor cell lines indicated relevance of this mechanism for human neoplasia. Our detection of the NDF/heregulin transcript in NIH3T3 cells implicates an autocrine loop involving this ligand in signaling by the ErbB3-ErbB2 heterodimer in the model system, whereas heregulin-independent mechanisms likely exist for cooperative signaling by ErbB3 and ErbB2 chronically activated in some human mammary carcinomas.
Similar articles
- Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH. Alimandi M, et al. EMBO J. 1997 Sep 15;16(18):5608-17. doi: 10.1093/emboj/16.18.5608. EMBO J. 1997. PMID: 9312020 Free PMC article. - ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. Grasso AW, et al. Oncogene. 1997 Nov 27;15(22):2705-16. doi: 10.1038/sj.onc.1201447. Oncogene. 1997. PMID: 9400997 - The role of the neu oncogene product in cell transformation and normal development.
Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen J, Hamuro J, Weiner DB, Greene MI. Kokai Y, et al. Princess Takamatsu Symp. 1988;19:45-57. Princess Takamatsu Symp. 1988. PMID: 2908355 Review. - Structural requirements for ErbB2 transactivation.
Penuel E, Schaefer G, Akita RW, Sliwkowski MX. Penuel E, et al. Semin Oncol. 2001 Dec;28(6 Suppl 18):36-42. Semin Oncol. 2001. PMID: 11774204 Review.
Cited by
- Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.
He J, Zeng X, Wang C, Wang E, Li Y. He J, et al. MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39070179 Free PMC article. Review. - The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
High P, Guernsey C, Subramanian S, Jacob J, Carmon KS. High P, et al. Pharmaceutics. 2024 Jul 2;16(7):890. doi: 10.3390/pharmaceutics16070890. Pharmaceutics. 2024. PMID: 39065587 Free PMC article. Review. - A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
Golbourn B, Ho B, Bondoc A, Luck A, Fan X, Richardson E, Marcellus R, Prakesch M, Halbert M, Agrawal N, Smith C, Huang A, Rutka JT. Golbourn B, et al. Neuro Oncol. 2024 Oct 3;26(10):1895-1911. doi: 10.1093/neuonc/noae120. Neuro Oncol. 2024. PMID: 38981018 - Busting the Breast Cancer with AstraZeneca's Gefitinib.
Chemmalar S, Intan Shameha AR, Che Abdullah CA, Ab Razak NA, Yusof LM, Ajat M, Chan KW, Abu Bakar Zakaria MZ. Chemmalar S, et al. Adv Pharmacol Pharm Sci. 2023 Dec 4;2023:8127695. doi: 10.1155/2023/8127695. eCollection 2023. Adv Pharmacol Pharm Sci. 2023. PMID: 38090376 Free PMC article. Review. - HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
Majumder A. Majumder A. Cells. 2023 Oct 25;12(21):2517. doi: 10.3390/cells12212517. Cells. 2023. PMID: 37947595 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous